A Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder
Status:
Not yet recruiting
Trial end date:
2023-07-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of ascending oral doses
of CYB003 in participants with major depressive disorder (MDD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cybin IRL Limited
Collaborators:
Clinilabs Drug Development Corporation Drug Safety Navigator